Latest Strategy News

Great Divide Mining has poured its first gold at the Challenger Gold Mine, marking a key milestone as it moves from exploration to production. The company raised $1.335 million to support its ramp-up plans amid ongoing joint venture challenges.

Celsius Resources reports steady progress on its Maalinao-Caigutan-Biyog copper-gold project, supported by promising drilling outcomes and critical bridge financing. The company also advances social and environmental initiatives while preparing for operational readiness.

Austral Gold’s Q3 report reveals a sharp production drop at Guanaco following a fatal accident, prompting a downward revision of 2025 output and cost hikes, while Casposo’s refurbishment signals a new growth phase.

DXN Limited reports a sharp revenue decline in Q1 FY26 due to client-driven project deferrals but highlights a robust $11.9 million backlog and the imminent launch of its first Data Centre as a Service site.

Novatti Group has achieved positive operating cashflow and EBITDA for the September quarter, driven by strategic revenue reforms and new commercial contracts with major clients.

Xstate Resources has secured $3.82 million through a two-tranche capital raising to advance appraisal and production testing at its Diona-1 well in Queensland, positioning the company for critical flow testing and further exploration.

Livium Ltd has completed its strategic pivot to focus on recycling clean energy waste, reporting solid Q1 FY26 results and securing a significant capital raise to fuel expansion into battery, solar panel, and rare-earth element recycling.

Savannah Goldfields Limited has completed key maintenance and recommissioning at its Georgetown Gold Processing Plant, targeting a first gold pour in early November 2025. Mining at Big Reef is set to begin shortly, with Agate Creek operations planned for next year.

BCAL Diagnostics has secured key partnerships and a $10 million convertible note facility to expand its cancer detection tests across Australia and New Zealand, marking steady commercial progress in Q3 2025.

Bubs Australia reported a 30% increase in net revenue to $25.6 million for Q1 FY26, driven by robust US sales and a return to profitability with positive EBITDA. Despite inventory challenges in other regions, the company maintains a solid cash position and anticipates FDA approval by year-end.

PainChek Ltd has achieved a pivotal FDA De Novo clearance for its AI-driven Adult pain assessment app, unlocking the US market and driving its annual recurring revenue to $5.6 million. The company also launched its Infant app, targeting a vast global market of pre-verbal children.

Pathkey.AI reports strong validation of its TrialKey AI platform’s predictive accuracy and announces key leadership changes as it advances toward commercial scale.